Oxidative Stress Promotes Doxorubicin-Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions

Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells

(2015) Giovanna Mirone et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Increased Oxidative Stress as a Selective Anticancer Therapy

(2015) Jiahui Liu et al.   Oxidative Medicine and Cellular Longevity

Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype

(2015) Haiquan Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug Resistance

(2015) Eran E. Bram et al.   NEOPLASIA

Targeting antioxidants for cancer therapy

(2014) Andrea Glasauer et al.   BIOCHEMICAL PHARMACOLOGY

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

HIF-1α Inhibition Reverses Multidrug Resistance in Colon Cancer Cells via Downregulation of MDR1/P-Glycoprotein

(2014) Jianfang Chen et al.   PLoS One

Is redox signaling a feasible target for overcoming multidrug resistance in cancer chemotherapy?

(2014) Manuela Polimeni et al.   Frontiers in Pharmacology

MicroRNA-195 Chemosensitizes Colon Cancer Cells to the Chemotherapeutic Drug Doxorubicin by Targeting the First Binding Site of BCL2L2 mRNA

(2013) Juan Qu et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1

(2012) Bray Denard et al.   eLife

Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma

(2011) Changjun He et al.   CANCER SCIENCE

Impact of APE1/Ref-1 Redox Inhibition on Pancreatic Tumor Growth

(2011) M. L. Fishel et al.   MOLECULAR CANCER THERAPEUTICS

Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR

(2011) M Caraglia et al.   Cell Death & Disease

Review: Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects

(2010) Diogo Assed Bastos et al.   Therapeutic Advances in Medical Oncology

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

(2009) Dunyaporn Trachootham et al.   NATURE REVIEWS DRUG DISCOVERY

Treatment of resistant human colon cancer xenografts by a fluoxetine–doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen

(2008) Mirit Argov et al.   CANCER LETTERS

RhoA Silencing Reverts the Resistance to Doxorubicin in Human Colon Cancer Cells

(2008) S. Doublier et al.   MOLECULAR CANCER RESEARCH

Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity

(2008) R. Sullivan et al.   MOLECULAR CANCER THERAPEUTICS

Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells

(2008) R. C-Y. Hui et al.   MOLECULAR CANCER THERAPEUTICS